Oxcarbazepine (All indications)

Polydactyly

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9074
R31065		 Tomson (Oxcarbazepine), 2018 Polydactyly at least 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 22.75 [0.92;559.55] C 1/333   0/2,514 1 333
ref
S9065
R30947		 Viinikainen (Oxcarbazepine) (Controls unexposed, sick) a, 2006 Polydactyly throughout pregnancy prospective cohort unexposed, sick Adjustment: No 34.33 [0.49;2389.88] C 0/2   0/52 0 2
ref
Total 2 studies 26.41 [2.05;340.38] 1 335
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Tomson (Oxcarbazepine), 2018Tomson, 2018 1 22.75[0.92; 559.55]133364%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Viinikainen (Oxcarbazepine) (Controls unexposed, sick) a, 2006Viinikainen, 2006 2 34.33[0.49; 2389.88]0236%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 26.41[2.05; 340.38]13350.9100.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Oxcarbazepine; 2: Oxcarbazepine) (Controls unexposed, sick) ;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 26.41[2.05; 340.38]13350%NATomson (Oxcarbazepine), 2018 Viinikainen (Oxcarbazepine) (Controls unexposed, sick) a, 2006 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 34.33[0.49; 2389.88]-2 -NAViinikainen (Oxcarbazepine) (Controls unexposed, sick) a, 2006 1 exposed to other treatment, sickexposed to other treatment, sick 22.75[0.92; 559.55]1333 -NATomson (Oxcarbazepine), 2018 1 Tags Adjustment   - No  - No 26.41[2.05; 340.38]13350%NATomson (Oxcarbazepine), 2018 Viinikainen (Oxcarbazepine) (Controls unexposed, sick) a, 2006 2 All studiesAll studies 26.41[2.05; 340.38]13350%NATomson (Oxcarbazepine), 2018 Viinikainen (Oxcarbazepine) (Controls unexposed, sick) a, 2006 20.5100.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls Out of scale34.33[0.49; 2389.88]-2 -NAViinikainen (Oxcarbazepine) (Controls unexposed, sick) a, 2006 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls Out of scale22.75[0.92; 559.55]1333 -NATomson (Oxcarbazepine), 2018 10.510.01.0